Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15–36
CAS
Article
PubMed
Google Scholar
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6
CAS
Article
PubMed
Google Scholar
Goff BA, Mandel LS, Melancon CH, Muntz HG (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705–2712
CAS
Article
PubMed
Google Scholar
Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329:1550–1559
CAS
Article
PubMed
Google Scholar
Runnowicz CD, Fields AL (1999) Screening for gynecologic malignancies: a continuing responsibility. Surg Oncol Clin N Am 8:703–724
Google Scholar
Bast RC Jr (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21:200–205
Article
Google Scholar
Sidransky D (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2:210–219
CAS
Article
PubMed
Google Scholar
Dehaghani AS, Shahriary K, Kashef MA, Naeimi S, Fattahi MJ, Mojtahedi Z, Ghaderi A (2009) Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep 36:2393–2397
Article
Google Scholar
Xu F, Wang G, Cai K, Zhai R, Tang S (2010) Effects of ovariectomy on microsatellite instability in rat colon tumors induced by 1,2-dimethylhydrazine. Mol Biol Rep 37:1397–1401
CAS
Article
PubMed
Google Scholar
Liao R-Y, Mao C, Qiu L-X, Ding H, Chen Q, Pan H-F (2009) TGFBR1*6A/9A polymorphism and cancer risk: a meta analysis of 13,662 cases and 14,147 controls. Mol Biol Rep. doi:10.1007/s11033-009-9906-7
Boyd J (1998) Molecular genetics of hereditary ovarian cancer. Oncology (Huntingt) 12:399–406
CAS
Google Scholar
Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, Andrulis IL, Lu J, Ho FC (1999) Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 18:4643–4646
CAS
Article
PubMed
Google Scholar
Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A (1995) A somatic BRCA1 mutation in an ovarian tumor. Nat Genet 9:343–344
CAS
Article
PubMed
Google Scholar
Dobrovick A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347–3350
Google Scholar
Wilson CA, Ramos L, Villasenar MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236–240
CAS
Article
PubMed
Google Scholar
Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523–535
CAS
Article
PubMed
Google Scholar
Hilton JL, Geisler JP, Rathe JA, Zogg H, DeYoung B, Buller RE (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396–1406
CAS
PubMed
Google Scholar
Ekblad CM, Chavali GB, Basu BP, Freund SM, Veprintsev D, Hughes-Davies L, Kouzarides T, Doherty AJ, Itzhaki LS (2005) Binding of EMSY to HP1β: implications for recruitment of HP1β and BS69. EMBO Rep 6:675–680
CAS
Article
PubMed
Google Scholar
Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324
CAS
Article
PubMed
Google Scholar
Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C (1994) Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosom Cancer 9:42–48
CAS
Article
PubMed
Google Scholar
Bekri S, Adélaïde J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pébusque MJ, Theillet C, Birnbaum D, Gaudray P (1997) Detailed map of a region commonly amplified at 11q13 → q14 in human breast carcinoma. Cytogenet Cell Genet 79:125–131
CAS
Article
PubMed
Google Scholar
Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H (2003) Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5–q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163:985–992
CAS
PubMed
Google Scholar
Nordling M, Karlsson P, Wahlström J, Engwall Y, Wallgren A, Martinsson T (1998) A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58:1372–1375
CAS
PubMed
Google Scholar
Rodriguez C, Hughes-Davies L, Vallès H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C (2004) Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 10:5785–5791
CAS
Article
PubMed
Google Scholar
Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D (2006) Amplification of EMSY, a novel oncogene on 11q13 in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100:264–270
CAS
Article
PubMed
Google Scholar